<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41972">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049424</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-03/2011</org_study_id>
    <nct_id>NCT02049424</nct_id>
  </id_info>
  <brief_title>Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow</brief_title>
  <official_title>Retrospective-prospective Observational Study for Data Collection of Patients Who Underwent an Haploidentical Transplantation After Non-myeloablative Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outcome evaluation in patients who underwent transplantation with T-repleted bone marrow
      after post-transplantation cyclophosphamide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who underwent transplantation with T-repleted bone marrow haploidentical
      transplantation will be analyzed considering toxicity incidence (GVHD, infective
      complications, graft-failure incidence and TRM)and efficacy variables (Overall Survival,
      Progression Free Survival and Relapse incidence)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>toxicity evaluation</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Chronic and acute GVHD, infectious complications, graft failure, TRM</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>transplanted patients</arm_group_label>
    <description>T-repleted haploidentical transplanted patients in Italy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent a haploidentical transplantion after non-myeloablative conditioning
        regimen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients affected by hematologic neoplasia who underwent a haploidentical
        transplantation (2-3 mismatches) from a familiar donor, with non-ex vivo manipulated bone
        marrow and post-transplantation cyclophosphamide

        Exclusion Criteria:

          -  ex vivo manipulated bone marrow transplantation

          -  use of antilymphocyte serum during conditioning
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Castagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
